Prazosin is NOT Recommended for Headache Prophylaxis
Prazosin should not be used for routine headache prophylaxis. The drug is FDA-approved only for hypertension treatment 1, and there is no guideline support for its use in migraine prevention. While one small pilot study showed promise for post-traumatic headaches specifically, this does not translate to general headache prophylaxis recommendations.
Evidence Assessment
Guideline Recommendations - What Actually Works
The most recent and authoritative guidelines consistently identify first-line agents for migraine prophylaxis that do NOT include prazosin:
- Propranolol (80-240 mg/d) and timolol (20-30 mg/d) are the recommended beta-blockers 2, 3
- Amitriptyline (30-150 mg/d) 2
- Divalproex sodium (500-1500 mg/d) or sodium valproate (800-1500 mg/d) 2
- Newer CGRP antagonists (erenumab, fremanezumab, galcanezumab) for episodic or chronic migraine 4
- Candesartan or telmisartan (ARBs, not alpha-blockers) for episodic migraine 4
Why Prazosin Doesn't Make the Cut
Alpha-1 blockers are conspicuously absent from all major guidelines. The 2002 U.S. Headache Consortium guidelines reviewed alpha-2 agonists (clonidine, guanfacine) but found no evidence for efficacy of clonidine and only limited evidence for guanfacine 2. Prazosin, as an alpha-1 blocker, was not even evaluated in these comprehensive reviews.
The Limited Research Evidence
Only one randomized controlled pilot trial (2023) examined prazosin specifically for headache prophylaxis 5:
- Context-specific: Post-traumatic headaches in military personnel following mild traumatic brain injury
- Small sample: 48 participants (32 prazosin, 16 placebo)
- Significant adverse effects: 69% experienced morning drowsiness/lethargy vs 19% placebo (p=0.002)
- Authors' conclusion: Called for larger trials to confirm results - this has not occurred
The only other mentions of prazosin and headache are:
- A 1997 anecdotal case series of 10 patients with mixed results and 50% discontinuation due to side effects 6
- Case reports of prazosin treating headaches as a side effect of other conditions (post-endarterectomy, pheochromocytoma) 7, 8
FDA-Approved Indication and Safety Profile
Prazosin is FDA-approved only for hypertension 1. The FDA label lists headache as a common adverse effect (7.8% incidence) 1, which is counterproductive for headache prophylaxis. Other concerning adverse effects include:
- Syncope with sudden loss of consciousness (1% with initial doses ≥2 mg) 1
- Dizziness (10.3%), drowsiness (7.6%), weakness (6.5%) 1
- Orthostatic hypotension requiring careful dose titration 1
Clinical Algorithm for Migraine Prophylaxis
When to initiate prophylaxis 2:
- ≥2 attacks/month producing disability lasting ≥3 days/month
- Contraindication to or failure of acute treatments
- Use of abortive medication >2 times/week
- Uncommon migraine conditions (hemiplegic migraine, prolonged aura, migrainous infarction)
First-line agent selection:
- Propranolol 80-240 mg/d - strongest evidence, use if no contraindications (asthma, heart block, depression) 2, 3
- Amitriptyline 30-150 mg/d - especially if comorbid tension-type headache or insomnia 2
- Divalproex/valproate - if prolonged aura or atypical features; avoid in women of childbearing potential 2
- Candesartan or telmisartan - if comorbid hypertension 4
- CGRP antagonists - if first-line agents fail or are contraindicated, though cost may be prohibitive 3, 4
Titration approach: Start low, increase slowly over 2-3 months to assess efficacy before declaring treatment failure 2.
Common Pitfalls
- Don't use prazosin off-label for migraine prophylaxis - no guideline support, headache is actually a side effect
- Don't confuse alpha-1 blockers (prazosin) with beta-blockers (propranolol) - only beta-blockers without intrinsic sympathomimetic activity work for migraine
- Don't confuse with ARBs - while candesartan/telmisartan (ARBs) are recommended 4, prazosin (alpha-1 blocker) is not
- The single positive pilot study 5 was for post-traumatic headaches in a highly specific military population, not general migraine prophylaxis
If a patient specifically has post-traumatic headaches following mild TBI, prazosin might be considered as an investigational option based on the 2023 pilot trial 5, but this remains off-label and requires informed consent about limited evidence and high adverse effect rates.